Translational Approach to Predicting the Efficacy of Maraviroc-Based Regimens as HIV Preexposure Prophylaxis

Authors:

Abstract
Maraviroc-based regimens have been explored as preexposure prophylaxis (PrEP) against human immunodeficiency virus (HIV). In this study, we utilized mucosal tissue drug exposure data, combined with target concentrations generated in vitro , in a pharmacokinetic-pharmacodynamic analysis to predict the effects of drug combinations and adherence on PrEP efficacy. Mucosal tissue concentrations of maraviroc were measured in 24 healthy women.
Funding Information
  • HHS | NIH | National Institute of Allergy and Infectious Diseases (U01 AU095031)
  • HHS | NIH | National Institute of General Medical Sciences (T32 GM086330)
  • UNC | UNC-CH | Center for AIDS Research, University of North Carolina at Chapel Hill (P30 AI50410)

This publication has 31 references indexed in Scilit: